StockpollyBeta
Get App
Popularity #3,040
NKTX · NASDAQ · Biotechnology

Nkarta (NKTX)

Develops NKX019-led CAR NK therapies for B-cell autoimmune diseases.

$2.95
After hours+0.01 (+0.17%)
At close$2.95(+2.26%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue002000000020
Gross profit00−20000000−20
293131313431372727312943
Research & development222323232523242120252329
7788987676614
General & administrative7788987676614
Other expenses010000500000
Operating income−29−31−33−31−34−31−37−27−27−31−31−43
433655546433
Interest income433655444333
Other non-operating income0−1−3−6−5−5−5−4−6−4−3−3
Income before tax−26−28−30−25−28−26−32−23−22−27−28−40
Net income from continuing operations−26−28−30−25−28−26−32−23−22−27−28−40
Net income−26−28−30−25−28−26−32−23−22−27−28−40
EPS, basic−$0.52−$0.57−$0.58−$0.34−$0.39−$0.35−$0.43−$0.31−$0.29−$0.37−$0.37−$0.54
EPS, diluted−$0.52−$0.57−$0.58−$0.34−$0.39−$0.35−$0.43−$0.31−$0.29−$0.37−$0.37−$0.54
Weighted average shares, basic494951737474747474747474
Weighted average shares, diluted494951737474747474747474
EBITDA−27−28−27−23−26−24−29−21−19−25−25−38
Depreciation & amortization222222222223
EBIT−29−30−30−25−28−26−31−23−22−27−28−40